Page last updated: 2024-12-05

apiole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Apiole is a naturally occurring furanocoumarin found in parsley, celery, and other plants of the Apiaceae family. It is a colorless liquid with a sweet, spicy aroma. Apiole has been studied for its potential biological activities, including antimicrobial, anti-inflammatory, and anti-cancer properties. Its synthesis involves various chemical processes, such as extraction from plant material and subsequent purification. Apiole is also known to exhibit estrogenic activity, which may have implications for human health. Its potential therapeutic benefits are being explored, and research is ongoing to understand its mechanisms of action and potential applications in medicine.'

apiole: crystalline essential oil isolated directly from commercial oil of parsley [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID10659
CHEMBL ID1560118
CHEBI ID70353
SCHEMBL ID497412
MeSH IDM0414249

Synonyms (77)

Synonym
4,7-dimethoxy-5-(2-propen-1-yl)-1,3-benzodioxole
qq67504pxo ,
1,3-benzodioxole, 4,7-dimethoxy-5-(2-propen-1-yl)-
unii-qq67504pxo
AKOS003398564
1,3-benzodioxole, 4,7-dimethoxy-5-(2-propenyl)-
SPECTRUM_000400
SPECTRUM4_001643
apiole (parsley)
petersiliencampher
ai3-14843
brn 0195747
5-allyl-4,7-dimethoxy-1,3-benzodioxol
einecs 208-349-2
benzene, 1-allyl-2,5-dimethoxy-3,4-(methylenedioxy)-
parsley apiol
1-allyl-2,5-dimethoxy-3,4-methylenedioxybenzene
5-allyl-4,7-dimethoxy-1,3-benzodioxole
nsc 9070
nsc-9070
apioline
parsley camphor
1-allyl-2,4-(methylenedioxy)benzene
nsc9070 ,
wln: t56 bo do chj fo1 h2u1 io1
1, 4,7-dimethoxy-5-(2-propenyl)-
parsley apiole
apiol
benzene,5-dimethoxy-3,4-(methylenedioxy)-
SPECTRUM5_001718
523-80-8
apiole
NCGC00094551-02
NCGC00094551-01
KBIOGR_002105
KBIO3_002105
KBIO2_003448
KBIOSS_000880
KBIO2_000880
KBIO2_006016
SPECTRUM3_001283
SPECTRUM2_000419
SPBIO_000378
SPECTRUM390001
BSPBIO_002885
NCGC00094551-03
4,7-dimethoxy-5-prop-2-enyl-1,3-benzodioxole
4,7-dimethoxy-5-(prop-2-en-1-yl)-1,3-benzodioxole
STK664284
chebi:70353 ,
CHEMBL1560118
CCG-39582
FT-0632286
apiole (parsley) [mi]
apiolum
apiolum [hpus]
apiole [vandf]
apiole, parsley
4,7-dimethoxy-5-(2-propenyl)-1,3-benzodioxole
SCHEMBL497412
4,7-dimethoxy-5-(2-propanyl)-1,3-benzodioxole
5-allyl-4,7-dimethoxy-1,3-benzodioxole #
1-allyl-2,5-dimethoxy-3,4-(methylenedioxy)benzene
DTXSID4041236
4,7-dimethoxy-5-(prop-2-en-1-yl)-2h-1,3-benzodioxole
mfcd00047270
4,7-dimethoxy-5-(2-propanyl)-1,3-benzodioxole, aldrichcpr
SR-05000002460-1
sr-05000002460
4,7-dimethoxy-5-(2-propenyl)-1,3-benzodioxole, 9ci
1-allyl-2,5-dimethoxy-3,4-(methylenedioxy)-benzene
1-allyl-2,5-dimethoxy-3, 4-(methylenedioxy)benzene
camphre de persil
Q21071561
5-allyl-4,7-dimethoxybenzo[d][1,3]dioxole
5-allyl-4,7-dimethoxy-benzo-1,3-dioxole
apiol1503

Research Excerpts

Actions

ExcerptReferenceRelevance
"The apiole-induced increase in G0/G1 phase cell cycle regulators was also associated with a significant decrease in the expression of cyclins D1 and D3."( The in vivo antitumor effects on human COLO 205 cancer cells of the 4,7-dimethoxy-5-(2-propen-1-yl)-1,3-benzodioxole (apiole) derivative of 5-substituted 4,7-dimethoxy-5-methyl-l,3-benzodioxole (SY-1) isolated from the fruiting body of Antrodia camphorate
Chang, CH; Chang, HW; Chen, CS; Chen, LC; Ho, YS; Huang, CS; Lien, HM; Tseng, H; Tu, SH; Wei, PL; Wu, CH,
)
0.82

Dosage Studied

ExcerptRelevanceReference
") injection three times per week (defined as a dosage of 1×-30×)."( The in vivo antitumor effects on human COLO 205 cancer cells of the 4,7-dimethoxy-5-(2-propen-1-yl)-1,3-benzodioxole (apiole) derivative of 5-substituted 4,7-dimethoxy-5-methyl-l,3-benzodioxole (SY-1) isolated from the fruiting body of Antrodia camphorate
Chang, CH; Chang, HW; Chen, CS; Chen, LC; Ho, YS; Huang, CS; Lien, HM; Tseng, H; Tu, SH; Wei, PL; Wu, CH,
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
benzodioxoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (20)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency3.98110.012610.691788.5700AID887
USP1 protein, partialHomo sapiens (human)Potency100.00000.031637.5844354.8130AID504865
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency2.81840.00798.23321,122.0200AID2546
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency7.94330.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency7.94331.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1594145Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding by measuring rhodanese enzyme activity 2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID550213Antimitotic activity against Paracentrotus lividus embryo assessed as cleavage alteration up to 80 to 100 uM after 2.5 to 6 hrs post fertilization by sea urchin embryo assay2010Journal of natural products, Nov-29, Volume: 73, Issue:11
Synthesis of antimitotic polyalkoxyphenyl derivatives of combretastatin using plant allylpolyalkoxybenzenes.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1594144Inhibition of Escherichia coli GroEL expressed in Escherichia coliDH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured soluble pig heart MDH refolding by measuring MDH enzyme acti2019Bioorganic & medicinal chemistry letters, 05-01, Volume: 29, Issue:9
HSP60/10 chaperonin systems are inhibited by a variety of approved drugs, natural products, and known bioactive molecules.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (22)

TimeframeStudies, This Drug (%)All Drugs %
pre-19907 (31.82)18.7374
1990's0 (0.00)18.2507
2000's4 (18.18)29.6817
2010's10 (45.45)24.3611
2020's1 (4.55)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 62.26

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index62.26 (24.57)
Research Supply Index3.30 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index99.14 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (62.26)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (3.85%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other25 (96.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]